NO20092671L - Antistoffer mot human cytomegalovirus (HCMV) - Google Patents

Antistoffer mot human cytomegalovirus (HCMV)

Info

Publication number
NO20092671L
NO20092671L NO20092671A NO20092671A NO20092671L NO 20092671 L NO20092671 L NO 20092671L NO 20092671 A NO20092671 A NO 20092671A NO 20092671 A NO20092671 A NO 20092671A NO 20092671 L NO20092671 L NO 20092671L
Authority
NO
Norway
Prior art keywords
hcmv
human cytomegalovirus
antibodies
infections
sequences
Prior art date
Application number
NO20092671A
Other languages
English (en)
Norwegian (no)
Inventor
Ada Funaro
Giorgio Gribaudo
Santo Landolfo
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2006/069780 external-priority patent/WO2007068758A1/en
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Publication of NO20092671L publication Critical patent/NO20092671L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20092671A 2006-12-15 2009-07-14 Antistoffer mot human cytomegalovirus (HCMV) NO20092671L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2006/069780 WO2007068758A1 (en) 2005-12-16 2006-12-15 Methods for obtaining immortalized antibody secreting cells
EP07110693 2007-06-20
PCT/EP2007/064094 WO2008071806A1 (en) 2006-12-15 2007-12-17 Antibodies against human cytomegalovirus (hcmv)

Publications (1)

Publication Number Publication Date
NO20092671L true NO20092671L (no) 2009-09-03

Family

ID=40935039

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092671A NO20092671L (no) 2006-12-15 2009-07-14 Antistoffer mot human cytomegalovirus (HCMV)

Country Status (18)

Country Link
US (1) US8153129B2 (pt)
EP (1) EP2126049B1 (pt)
JP (1) JP5351041B2 (pt)
KR (1) KR20090114364A (pt)
CN (1) CN101627115B (pt)
AT (1) ATE503769T1 (pt)
AU (1) AU2007331463B2 (pt)
BR (1) BRPI0720464A2 (pt)
CA (1) CA2672703C (pt)
DE (1) DE602007013618D1 (pt)
DK (1) DK2126049T3 (pt)
EA (1) EA018701B1 (pt)
ES (1) ES2363992T3 (pt)
IL (1) IL199366A (pt)
NO (1) NO20092671L (pt)
PL (1) PL2126049T3 (pt)
PT (1) PT2126049E (pt)
WO (1) WO2008071806A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US20110171233A1 (en) * 2007-08-22 2011-07-14 Ribovax Biotechnologies S.A. Antibodies Against Human Cytomegalovirus (HCMV)
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
US8703486B2 (en) * 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
BR112014024023A2 (pt) 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
KR101581158B1 (ko) 2014-03-26 2015-12-30 울산대학교 산학협력단 거대세포바이러스 실제 감염 여부를 진단하기 위한 거대세포바이러스의 감염 해석 모델
CN106255757B (zh) * 2014-05-19 2020-08-11 豪夫迈·罗氏有限公司 生产多肽的方法
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1445243A (zh) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 抗人巨细胞病毒人源中和性基因工程Fab抗体
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders

Also Published As

Publication number Publication date
CA2672703C (en) 2016-11-22
US20100040602A1 (en) 2010-02-18
WO2008071806A1 (en) 2008-06-19
EA200970586A1 (ru) 2009-12-30
JP5351041B2 (ja) 2013-11-27
CN101627115B (zh) 2013-05-29
CN101627115A (zh) 2010-01-13
AU2007331463B2 (en) 2014-03-27
DK2126049T3 (da) 2011-07-18
PT2126049E (pt) 2011-07-04
PL2126049T3 (pl) 2011-09-30
ES2363992T3 (es) 2011-08-22
DE602007013618D1 (de) 2011-05-12
AU2007331463A1 (en) 2008-06-19
EP2126049B1 (en) 2011-03-30
EA018701B1 (ru) 2013-10-30
US8153129B2 (en) 2012-04-10
IL199366A (en) 2015-03-31
BRPI0720464A2 (pt) 2014-01-14
EP2126049A1 (en) 2009-12-02
CA2672703A1 (en) 2008-06-19
KR20090114364A (ko) 2009-11-03
ATE503769T1 (de) 2011-04-15
JP2010512736A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
NO20092671L (no) Antistoffer mot human cytomegalovirus (HCMV)
EA201000424A1 (ru) Антитела к il-23
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
EP2336174B8 (en) Human monoclonal antibodies against Hendra and Nipah viruses
WO2007120626A3 (en) Uses and compositions for treatment of ankylosing spondylitis
PH12012501308A1 (en) Binding members for human cytomegalovirus
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
NO20054170L (no) Antistoff mot human IL-21 reseptor og anvendelser derav
EA200901490A1 (ru) Химические соединения
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
NO20091655L (no) Substituerte dihydropyrazoloner for behandling av kardiovaskulaere og hematologiske sykdommer
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
NO20091321L (no) Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201001212A8 (ru) Лечение микробных инфекций
NO20083697L (no) Fremgangsmater for anvendelse av antistoffer mot human IL-22
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
EA201171237A1 (ru) Антитела к dkk-1
WO2014200898A3 (en) Cmv neutralizing antigen binding proteins
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EP2463304A3 (en) Monoclonal antibodies that neutralize anthrax toxins
WO2008057158A3 (en) Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application